Immunovant, Inc. (IMVT)
- Previous Close
30.70 - Open
30.69 - Bid 30.55 x 100
- Ask 30.69 x 100
- Day's Range
30.45 - 30.85 - 52 Week Range
18.16 - 45.58 - Volume
187,749 - Avg. Volume
1,096,108 - Market Cap (intraday)
4.447B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date May 21, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.86
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
immunovant.comRecent News: IMVT
Performance Overview: IMVT
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMVT
Valuation Measures
Market Cap
4.46B
Enterprise Value
3.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.15%
Return on Equity (ttm)
-44.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-243.45M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
690.94M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-125.81M
Research Analysis: IMVT
Company Insights: IMVT
IMVT does not have Company Insights